No glycemic benefit from guar administration in NIDDM.

No glycemic benefit from guar administration in NIDDM.

A randomized crossover study of 5-g guar minitablets against placebo, given three times per day with main meals for 8 wk, was done in 29 non-insulin-dependent diabetes mellitus (NIDDM) patients who had near-normal fasting plasma glucose concentrations on treatment with diet alone, additional sulfony...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Holman, R, Steemson, J, Darling, P, Turner, R
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	1987

Παρόμοια τεκμήρια

LACK OF BENEFIT FROM GUAR ADMINISTRATION IN WELL CONTROLLED NON-INSULIN-DEPENDENT DIABETIC-PATIENTS
ανά: Holman, R, κ.ά.
Έκδοση: (1984)

Insulin use in NIDDM. Rationale based on pathophysiology of disease.
ανά: Turner, R, κ.ά.
Έκδοση: (1990)

Treatment of NIDDM - Progressive requirement for polypharmacy to attain glycaemic goals
ανά: Cull, C, κ.ά.
Έκδοση: (1997)

Effects of ethnicity on metabolic control during the first six years of NIDDM
ανά: Davis, T, κ.ά.
Έκδοση: (1997)

Coronary heart disease and risk factors in NIDDM--experience from the United Kingdom Prospective Diabetes Study.
ανά: Turner, R, κ.ά.
Έκδοση: (1997)

CIGMA as a tool in the study of NIDDM.
ανά: Turner, R, κ.ά.
Έκδοση: (1988)

Asymptomatic left ventricular diastolic dysfunction in NIDDM; evaluation and association with glycemic control
ανά: Muhammad Kashif, κ.ά.
Έκδοση: (2016-06-01)

Segregation analysis of NIDDM in Caucasian families.
ανά: Cook, J, κ.ά.
Έκδοση: (1994)

Post-prandial amylin concentrations are increased by sulphonylurea, but unchanged by basal insulin, in NIDDM
ανά: Rachman, J, κ.ά.
Έκδοση: (1996)

LACK OF BENEFIT FROM ACUTE ELEVATION OF PLASMA GLIBENCLAMIDE LEVELS BEFORE MEALS
ανά: Turner, R, κ.ά.
Έκδοση: (1984)

Glycaemic improvement over one year in a double-blind trial of acarbose in 1,946 NIDDM patients
ανά: Holman, R, κ.ά.
Έκδοση: (1996)

HUMAN ULTRALENTE INSULIN
ανά: Holman, R, κ.ά.
Έκδοση: (1983)

Risk factors predicting progression of diabetic retinopathy over six years in 1579 NIDDM patients
ανά: Stratton, I, κ.ά.
Έκδοση: (1996)

Changes in amylin and amylin-like peptide concentrations and beta-cell function in response to sulfonylurea or insulin therapy in NIDDM.
ανά: Rachman, J, κ.ά.
Έκδοση: (1998)

Pathogenesis of NIDDM--a disease of deficient insulin secretion.
ανά: Turner, R, κ.ά.
Έκδοση: (1988)

Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.
ανά: Rachman, J, κ.ά.
Έκδοση: (1997)

Human ultralente insulin.
ανά: Holman, R, κ.ά.
Έκδοση: (1984)

U.K. Prospective Diabetes Study 22. Effect of age at diagnosis on diabetic tissue damage during the first 6 years of NIDDM.
ανά: Davis, T, κ.ά.
Έκδοση: (1997)

UK prospective diabetes study (UKPDS) 14: association of angiotensin-converting enzyme insertion/deletion polymorphism with myocardial infarction in NIDDM.
ανά: Keavney, B, κ.ά.
Έκδοση: (1995)

Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy.
ανά: Rachman, J, κ.ά.
Έκδοση: (1997)

Effect of a whey/guar preload on glycemic control in people with type 2 diabetes
ανά: P. Clifton, κ.ά.
Έκδοση: (2016-06-01)

RESTING THE BETA-CELLS WITH INSULIN IN NIDDM DOES NOT IMPROVE BETA-CELL FUNCTION NOR PROINSULIN PROCESSING
ανά: Rachman, J, κ.ά.
Έκδοση: (1995)

Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement.
ανά: Holman, R, κ.ά.
Έκδοση: (1987)

TWICE-DAILY SUBCUTANEOUS HUMAN PROINSULIN PROVIDES A SATISFACTORY BASAL INSULIN SUPPLEMENT IN TYPE-2 (NON-INSULIN-DEPENDENT) DIABETIC-PATIENTS
ανά: Holman, R, κ.ά.
Έκδοση: (1987)

Post-prandial glycaemic reduction by an alpha-glucosidase inhibitor in type 2 diabetic patients with therapeutically attained basal normoglycaemia.
ανά: Holman, R, κ.ά.
Έκδοση: (1991)

Familial association and lambda s for diabetes, obesity, high triglycerides and low HDL-cholesterol in sibs of NIDDM patients
ανά: Levy, J, κ.ά.
Έκδοση: (1997)

Familial association and lambda s for diabetes, obesity, high triglycerides and low HDL-cholesterol in sibs of NIDDM patients.
ανά: Levy, J, κ.ά.
Έκδοση: (1997)

Thyroid dysfunction and its relation with diabetes mellitus (NIDDM)
ανά: H.R.Bazrafshan (M.D), κ.ά.
Έκδοση: (2000-03-01)

Glycemic index of split peas, rice (Binam), kidney beans, green peas, "Lavash" bread and broad bean kernels in NIDDM subjects
ανά: Darabi A, κ.ά.
Έκδοση: (2000-09-01)

Glycemic index of split peas, rice (Binam), kidney beans, green peas, "Lavash" bread and broad bean kernels in NIDDM subjects
ανά: Darabi A, κ.ά.
Έκδοση: (2000-06-01)

U.K. Prospective Diabetes Study. XV: Relationship of renin-angiotensin system gene polymorphisms with microalbuminuria in NIDDM.
ανά: Dudley, C, κ.ά.
Έκδοση: (1995)

A STUDY OF MOXONIDINE’S METABOLIC EFFECTS IN PATIENTS WITH ARTERIAL HYPERTENSION AND NIDDM
ανά: D. V. Nebieridze, κ.ά.
Έκδοση: (2001-04-01)

Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.
ανά: Rachman, J, κ.ά.
Έκδοση: (1996)

No evidence for excess allele-sharing on chromosome 2q (region of NIDDM1) in a large sibship collection
ανά: Cassell, P, κ.ά.
Έκδοση: (1997)

NASAL INSULIN OUTPATIENT STUDY IN TYPE-I DIABETES
ανά: Holman, R, κ.ά.
Έκδοση: (1992)

No evidence for mutations in a putative beta-cell ATP-sensitive K+ channel subunit in MODY, NIDDM, or GDM.
ανά: Zhang, Y, κ.ά.
Έκδοση: (1995)

Specific insulin and proinsulin in normal glucose tolerant first-degree relatives of NIDDM patients
ανά: R. Coifman, κ.ά.
Έκδοση: (1999-01-01)

Reduced sampling protocols in estimation of insulin sensitivity and glucose effectiveness using the minimal - model in NIDDM
ανά: Ismail, I.S., κ.ά.
Έκδοση: (1993)

A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM.
ανά: Neil, A, κ.ά.
Έκδοση: (1993)

Rapid restoration of normoglycaemia using intravenous insulin boluses.
ανά: Dunnett, J, κ.ά.
Έκδοση: (1990)